Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Psilocybin by Compass Pathways for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval
Psilocybin is under clinical development by Compass Pathways and currently in Phase II for Post-Traumatic Stress Disorder (PTSD). According to...
Psilocybin by Compass Pathways for Obsessive-Compulsive Disorder: Likelihood of Approval
Psilocybin is under clinical development by Compass Pathways and currently in Phase I for Obsessive-Compulsive Disorder. According to GlobalData, Phase...
Psilocybin by Compass Pathways for Anorexia Nervosa: Likelihood of Approval
Psilocybin is under clinical development by Compass Pathways and currently in Phase II for Anorexia Nervosa. According to GlobalData, Phase...
Psilocybin by Compass Pathways for Body Dysmorphic Disorder: Likelihood of Approval
Psilocybin is under clinical development by Compass Pathways and currently in Phase II for Body Dysmorphic Disorder. According to GlobalData,...
Psilocybin by Compass Pathways for Treatment Resistant Depression: Likelihood of Approval
Psilocybin is under clinical development by Compass Pathways and currently in Phase III for Treatment Resistant Depression. According to GlobalData,...
Psilocybin by Compass Pathways for Treatment Resistant Depression: Likelihood of Approval
Psilocybin is under clinical development by Compass Pathways and currently in Phase III for Treatment Resistant Depression. According to GlobalData,...
Psilocybin by Compass Pathways for Body Dysmorphic Disorder: Likelihood of Approval
Psilocybin is under clinical development by Compass Pathways and currently in Phase II for Body Dysmorphic Disorder. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Compass Pathways's Psilocybin?
Psilocybin is a small molecule commercialized by Compass Pathways, with a leading Phase III program in Treatment Resistant Depression. According...